We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).
- Authors
Fornecker, L.; Delwail, V.; Thieblemont, C.; Ghesquieres, H.; Bouabdallah, K.; Tilly, H.; Le Calloch, R.; Morschhauser, F.; Costello, R.; Slama, B.; Gyan, E.; Chauchet, A.; Ngirabacu, M.; Durot, E.; Choquet, S.; Capdupuy, C.; Le Goff, M.; Voillat, L.; Snauwaert, S.; Amorim, S.
- Abstract
R/R disease was defined as follows: (1) autologous stem-cell transplantation (ASCT) eligible patients who failed to achieve a CR after at least one salvage therapy, (2) patients in first relapse after ASCT or (3) patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment. Results from a phase II LYSA study (PIVeR) B Introduction: b The prognosis of patients with relapsed/refractory aggressive non-hodgkin lymphoma (R/R aNHL) remains poor with conventional immunochemotherapies.
- Subjects
NON-Hodgkin's lymphoma; IFOSFAMIDE; RITUXIMAB; DIFFUSE large B-cell lymphomas
- Publication
Hematological Oncology, 2023, Vol 41, p437
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_322